Completed PHASE4 INTERVENTIONAL 2-arm NCT02008110

Carbohydrate Antigen 125-guided Therapy in Heart Failure (CHANCE-HF)

A Randomized Controlled Trial of Carbohydrate Antigen 125-guided Therapy Among Patients Recently Discharged for Acute Heart Failure: Effect on 1-year Mortality or Readmission for Acute Heart Failure (CHANCE-HF).

Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

Conditions Heart Failure

Interventions CA125 guided strategy Standard treatment strategy

Updated 5 times since 2017 Last updated: Feb 3, 2016 Started: Dec 31, 2011 Primary completion: Jul 31, 2014 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Heart Failure and is currently completed. Fundación para la Investigación del Hospital Clínico de Valencia leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación para la Investigación del Hospital Clínico de Valencia
Ministerio de Sanidad, Servicios Sociales e Igualdad

Data source: Fundación para la Investigación del Hospital Clínico de Valencia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valencia, Spain